Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IPSC Hot Sheet
Join SI Premium – FREE
Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11).
For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades PayPal (PYPL) to Hold
- Canaccord Downgrades Driven Brands (DRVN) to Hold
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
